Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase IIIa Trials

@inproceedings{Sorli2013ElderlyPW,
  title={Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase IIIa Trials},
  author={Christopher Sorli and Mark L Warren and David S. Oyer and Henriette Mersebach and Thue Johansen and Stephen C. L. Gough},
  booktitle={Drugs & aging},
  year={2013}
}
BACKGROUND AND OBJECTIVE Elderly patients with diabetes are more vulnerable to the occurrence and effects of hypoglycaemia; therefore, treatments with low risk of hypoglycaemia are preferred in this population. This study aimed to compare hypoglycaemia rates between insulin degludec (IDeg) and insulin glargine (IGlar) in elderly patients. METHODS Hypoglycaemia data from patients ≥65 years of age with type 1 (T1DM) or type 2 (T2DM) diabetes from seven randomised, treat-to-target phase IIIa… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

Concentrated insulins: the new basal insulins

Therapeutics and clinical risk management • 2016
View 18 Excerpts
Highly Influenced

Diabetes in the elderly: Matching meds to needs.

The Journal of family practice • 2018
View 1 Excerpt

Review of the Next Generation of Long-Acting Basal Insulins: Insulin Degludec and Insulin Glargine.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists • 2017